amoxicillin; clavulanate potassium - Profile

What are the generic drug sources for amoxicillin; clavulanate potassium and what is the scope of freedom to operate?

Amoxicillin; clavulanate potassium is the generic ingredient in nine branded drugs marketed by Aurobindo Pharma, Aurobindo Pharma Ltd, Cipla, Deva Holding As, Hikma Pharms, Micro Labs, Micro Labs Ltd India, Sandoz, Sandoz Inc, Sun Pharm Inds Ltd, Teva, Us Antibiotics, Chartwell Rx, Apotex Inc, and Teva Pharms Usa, and is included in forty-nine NDAs. Additional information is available in the individual branded drug profile pages.

Summary for amoxicillin; clavulanate potassium

US Patents:	0
Tradenames:	9
Applicants:	15
NDAs:	49

Paragraph IV (Patent) Challenges for AMOXICILLIN; CLAVULANATE POTASSIUM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AUGMENTIN XR	Extended-release Tablets	amoxicillin; clavulanate potassium	1000 mg/62.5 mg	050785	1	2009-01-21

US Patents and Regulatory Information for amoxicillin; clavulanate potassium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aurobindo Pharma	AMOXICILLIN AND CLAVULANATE POTASSIUM	amoxicillin; clavulanate potassium	FOR SUSPENSION;ORAL	209371-001	Apr 19, 2019	AB	RX	No	No
Aurobindo Pharma	AMOXICILLIN AND CLAVULANATE POTASSIUM	amoxicillin; clavulanate potassium	FOR SUSPENSION;ORAL	209371-002	Apr 19, 2019	AB	RX	No	No
Aurobindo Pharma Ltd	AMOXICILLIN AND CLAVULANATE POTASSIUM	amoxicillin; clavulanate potassium	FOR SUSPENSION;ORAL	201090-001	Dec 20, 2011	AB	RX	No	No
Aurobindo Pharma Ltd	AMOXICILLIN AND CLAVULANATE POTASSIUM	amoxicillin; clavulanate potassium	FOR SUSPENSION;ORAL	201090-002	Dec 20, 2011	AB	RX	No	No

Expired US Patents for amoxicillin; clavulanate potassium

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Us Antibiotics	AUGMENTIN XR	amoxicillin; clavulanate potassium	TABLET, EXTENDED RELEASE;ORAL	050785-001	Sep 25, 2002	6,746,692
Us Antibiotics	AUGMENTIN XR	amoxicillin; clavulanate potassium	TABLET, EXTENDED RELEASE;ORAL	050785-001	Sep 25, 2002	7,250,176
Us Antibiotics	AUGMENTIN XR	amoxicillin; clavulanate potassium	TABLET, EXTENDED RELEASE;ORAL	050785-001	Sep 25, 2002	7,217,430
Us Antibiotics	AUGMENTIN XR	amoxicillin; clavulanate potassium	TABLET, EXTENDED RELEASE;ORAL	050785-001	Sep 25, 2002	6,783,773

Amoxicillin/Clavulanate Potassium: Patent Landscape and Investment Fundamentals

Last updated: February 19, 2026

Amoxicillin/clavulanate potassium is a combination antibiotic that inhibits beta-lactamase enzymes, extending the spectrum of amoxicillin. Its market is mature, characterized by extensive generic competition and established therapeutic use. Key patent considerations involve expired composition of matter patents, with remaining intellectual property focused on manufacturing processes, formulations, and specific medical uses. Investment analysis hinges on market share dynamics, generic pricing pressures, and the potential for lifecycle management through novel delivery systems or targeted indications.

What is the Current Patent Status for Amoxicillin/Clavulanate Potassium?

The foundational patents for amoxicillin and clavulanate potassium have long expired. The original composition of matter patents for amoxicillin, a penicillin derivative, and clavulanic acid, a beta-lactamase inhibitor, were granted in the mid-to-late 1970s and early 1980s. Consequently, both active pharmaceutical ingredients (APIs) are in the public domain.

However, intellectual property relevant to amoxicillin/clavulanate potassium persists. These secondary patents typically cover:

• Formulations: Novel salt forms, polymorphs, crystalline structures, and excipient combinations designed to improve stability, bioavailability, taste masking, or patient compliance. For example, patents may exist for specific ratios of amoxicillin to clavulanate, or for co-processed granules.
• Manufacturing Processes: Patented methods for synthesizing the APIs, purifying them, or combining them into the final dosage form. These can include specific crystallization techniques, solvent systems, or granulation methods that offer advantages in yield, purity, or cost.
• Dosage Regimens and Medical Uses: Patents for specific dosing schedules or the use of amoxicillin/clavulanate potassium to treat particular infections or patient populations. These can be driven by new clinical data demonstrating efficacy in previously unaddressed conditions or improved outcomes in existing ones.
• Delivery Systems: Innovations in how the drug is administered, such as extended-release formulations, film-coated tablets, or orally disintegrating tablets, can be patent-protected.

A significant portion of the remaining patent landscape focuses on the combination product itself, particularly novel synergistic formulations or improved stability profiles of the co-formulated drugs. As of late 2023, a review of patent databases reveals hundreds of active patents globally related to various aspects of amoxicillin and clavulanate potassium formulations and manufacturing. The expiration dates of these secondary patents vary widely, with many continuing into the mid-to-late 2020s and beyond for specific process or formulation innovations.

What are the Market Dynamics for Amoxicillin/Clavulanate Potassium?

The market for amoxicillin/clavulanate potassium is characterized by its high volume and extensive generic penetration. It is a cornerstone treatment for a broad range of bacterial infections, including respiratory tract infections, urinary tract infections, and skin and soft tissue infections.

Key market dynamics include:

• Generic Dominance: Following patent expirations, numerous generic manufacturers entered the market. This has led to intense price competition and a significant reduction in the average selling price (ASP) of amoxicillin/clavulanate potassium products. The market is highly fragmented with multiple suppliers.
• High Prescription Volume: Despite genericization, the drug's efficacy, broad spectrum of activity, and established safety profile maintain high prescription volumes globally. It remains a first-line or second-line option for many common infections.
• Geographic Variation: Market penetration and pricing can vary significantly by region due to differences in regulatory environments, healthcare reimbursement policies, and the competitive landscape of generic manufacturers. Developed markets often see more stringent quality controls on generics, while emerging markets may have a wider range of product qualities and pricing.
• Antimicrobial Stewardship Programs: The increasing focus on antimicrobial stewardship, aimed at combating antibiotic resistance, influences prescribing patterns. While amoxicillin/clavulanate potassium is still widely used, there is a push to reserve its use for specific indicated infections and to avoid overuse.
• Supply Chain Robustness: The mature nature of the drug's production means that established supply chains exist. However, disruptions can still occur due to raw material availability, manufacturing issues, or geopolitical factors, impacting price and availability.
• Brand vs. Generic Performance: Branded amoxicillin/clavulanate potassium (e.g., Augmentin) retains a market share, particularly in markets where healthcare providers and patients have established trust or where promotional efforts are strong. However, the vast majority of volume is now supplied by generic manufacturers.

Estimates of the global amoxicillin/clavulanate potassium market size vary but are generally in the multi-billion dollar range. For instance, the overall antibiotic market is projected to grow, and amoxicillin/clavulanate potassium, as a significant sub-segment, benefits from this trend. However, growth in this specific segment is often driven by volume rather than price increases.

What is the Competitive Landscape for Amoxicillin/Clavulanate Potassium?

The competitive landscape for amoxicillin/clavulanate potassium is exceptionally crowded, primarily due to the presence of a large number of generic manufacturers. This creates a highly competitive environment where differentiation is challenging and price is a primary determinant of market share.

Major players and competitive factors include:

• Generic Manufacturers: Companies such as Teva Pharmaceuticals, Viatris (formerly Mylan and Upjohn), Aurobindo Pharma, Sun Pharmaceutical Industries, and numerous others produce and market generic versions of amoxicillin/clavulanate potassium. These companies compete on manufacturing efficiency, cost of goods, distribution networks, and pricing strategies.
• Branded Manufacturer (Original Innovator): GlaxoSmithKline (GSK) was the originator of the brand-name product Augmentin. While GSK has faced significant generic competition, it continues to market its branded product and may have strategies to defend its market share through product line extensions or market access initiatives.
• Product Variations: Competition extends to different dosage strengths (e.g., 250mg/125mg, 500mg/125mg, 875mg/125mg) and dosage forms (tablets, suspensions). Some manufacturers may focus on specific variations where they have a competitive advantage in manufacturing or cost.
• Geographic Market Segmentation: Competition can be intense within specific countries or regions. For example, in the United States, numerous generic manufacturers compete for contracts with pharmacy benefit managers (PBMs) and retail pharmacy chains. In Europe, national tenders and differing regulatory approval processes shape competition.
• Emerging Market Players: Manufacturers from India and China play a significant role in the global supply of amoxicillin/clavulanate potassium, often offering highly competitive pricing.
• Regulatory Hurdles: While the APIs are off-patent, generic manufacturers must obtain regulatory approval (e.g., FDA Abbreviated New Drug Application (ANDA) in the US, or European Medicines Agency (EMA) Marketing Authorization Application (MAA) in Europe) for their finished products. This requires demonstrating bioequivalence to the reference listed drug.
• Quality and Compliance: Regulatory scrutiny on pharmaceutical manufacturing means that companies with strong quality control systems and a history of compliance are favored. This can create a barrier to entry for less established players.

The competitive environment effectively caps pricing potential for standard formulations, making cost-efficiency in manufacturing and distribution paramount for profitability.

What are the Investment Fundamentals and Risks for Amoxicillin/Clavulanate Potassium?

Investment in amoxicillin/clavulanate potassium, particularly through established generic manufacturers or companies with significant share in this segment, is primarily driven by volume and operational efficiency rather than significant revenue growth from new product introductions.

Investment Fundamentals:

• Stable Demand: The drug's essential nature and broad applicability ensure a consistent, high-volume demand, providing a predictable revenue stream for manufacturers.
• Manufacturing Scale and Cost Efficiency: Profitability for generic manufacturers hinges on their ability to produce amoxicillin/clavulanate potassium at a low cost of goods. Investments in efficient manufacturing processes, supply chain optimization, and economies of scale are critical.
• Market Share and Distribution: Companies with established distribution channels and significant market share in key geographies are well-positioned. Long-term contracts with large pharmacy chains or government tenders can provide revenue stability.
• Lifecycle Management Opportunities: While the core product is generic, there can be opportunities to invest in novel formulations (e.g., improved taste-masking suspensions for pediatrics, extended-release versions) or to secure patents on specific manufacturing processes that provide a cost or quality advantage. These represent niche opportunities for incremental value creation.
• Portfolio Diversification: For larger pharmaceutical companies, amoxicillin/clavulanate potassium contributes to a diversified portfolio of essential medicines, balancing risk across different therapeutic areas and product lifecycles.

Key Investment Risks:

• Intense Price Erosion: The primary risk is ongoing price erosion due to fierce generic competition. Manufacturers must constantly manage costs to maintain margins.
• Regulatory Scrutiny and Compliance: Pharmaceutical manufacturing is subject to stringent regulatory oversight. Any quality issues, manufacturing deviations, or import alerts can lead to production halts, product recalls, and significant financial penalties, severely impacting revenue and reputation.
• Antibiotic Resistance and Stewardship: Increasing concerns about antibiotic resistance may lead to more judicious prescribing of broad-spectrum antibiotics like amoxicillin/clavulanate potassium, potentially moderating volume growth or shifting treatment paradigms over the long term.
• Supply Chain Disruptions: Reliance on global supply chains for raw materials and intermediates makes the market susceptible to disruptions caused by geopolitical events, natural disasters, or raw material shortages, which can impact production costs and availability.
• Competition from New Antibiotics: While amoxicillin/clavulanate potassium is established, the development of novel antibiotics targeting similar or resistant pathogens could, over time, displace its use in certain indications.
• Intellectual Property Challenges: While core patents are expired, disputes over secondary patents (e.g., process patents, formulation patents) can arise, leading to litigation and potential injunctions or damages.

Investment decisions should focus on companies with a proven track record of efficient manufacturing, strong regulatory compliance, robust supply chain management, and effective strategies to navigate a highly competitive generic market.

What are the Regulatory Considerations for Amoxicillin/Clavulanate Potassium?

The regulatory landscape for amoxicillin/clavulanate potassium is multifaceted, encompassing approvals for new drug applications, post-market surveillance, and adherence to manufacturing quality standards.

Key regulatory considerations include:

• Abbreviated New Drug Applications (ANDAs) / Marketing Authorization Applications (MAAs): Generic manufacturers must submit comprehensive dossiers to regulatory agencies such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). These applications demonstrate bioequivalence to a reference listed drug (RLD), the innovator product, through pharmacokinetic studies. They also detail the manufacturing process, quality control measures, and impurity profiles.
• Good Manufacturing Practices (GMP): All facilities involved in the manufacturing, packaging, and testing of amoxicillin/clavulanate potassium must adhere to strict GMP regulations. Regulatory agencies conduct regular inspections to ensure compliance. Non-compliance can result in warning letters, import bans, or product seizures.
• Pharmacovigilance and Post-Market Surveillance: Manufacturers are responsible for monitoring and reporting adverse drug reactions (ADRs) associated with their products. This includes collecting data on side effects and reporting them to regulatory authorities.
• Labeling and Prescribing Information: Regulatory agencies scrutinize product labeling, including package inserts and patient information leaflets, to ensure accuracy, clarity, and completeness regarding indications, contraindications, warnings, precautions, and dosage.
• Impurity Limits and Stability Testing: Regulators set strict limits for impurities, including residual solvents and degradation products. Manufacturers must conduct extensive stability testing under various conditions to demonstrate that the drug product remains safe and effective throughout its shelf life. The stability of amoxicillin, particularly in the presence of moisture and heat, is a critical factor.
• Counterfeit Drug Prevention: Regulatory bodies and industry stakeholders are increasingly focused on preventing counterfeit or substandard medicines from entering the supply chain. Manufacturers must implement robust anti-counterfeiting measures.
• Antimicrobial Resistance Policies: While not directly regulating the drug's composition, regulatory bodies and public health agencies influence its use through guidelines and recommendations related to antimicrobial stewardship, which can indirectly impact market demand and prescribing practices.

Adherence to these regulations is non-negotiable and requires continuous investment in quality systems and personnel. Failure to comply can result in severe penalties, including loss of marketing authorization.

What are the Manufacturing and Supply Chain Considerations?

The manufacturing and supply chain for amoxicillin/clavulanate potassium are critical for ensuring consistent product availability and competitive pricing. Given the high volume and generic nature of the market, efficiency and resilience are paramount.

Manufacturing Considerations:

• API Sourcing: Amoxicillin is typically synthesized through semi-synthetic processes. Clavulanic acid is produced via fermentation of Streptomyces clavuligerus. Sourcing high-quality APIs from reliable suppliers is fundamental. Many API manufacturers are based in China and India.
• Formulation and Finishing: The process involves blending amoxicillin trihydrate or anhydrous amoxicillin with potassium clavulanate, along with various excipients such as fillers (e.g., microcrystalline cellulose), binders (e.g., povidone), disintegrants (e.g., croscarmellose sodium), lubricants (e.g., magnesium stearate), and coating agents. Precision in ratios and uniformity of content are critical.
• Stability Challenges: Amoxicillin and clavulanate potassium are susceptible to degradation, particularly clavulanate potassium which is sensitive to moisture and heat. Manufacturing processes and packaging must be designed to mitigate these issues. This often involves using desiccants in packaging and controlling humidity during manufacturing.
• Scale of Production: To achieve cost competitiveness, manufacturers operate large-scale production facilities capable of producing millions of tablets or capsules annually. Economies of scale are essential.
• Quality Control: Rigorous in-process and finished product testing is required to ensure compliance with pharmacopoeial standards (e.g., USP, EP, BP) for identity, purity, potency, dissolution, and uniformity of dosage units.

Supply Chain Considerations:

• Global Sourcing of Raw Materials: Key starting materials and excipients are sourced globally, necessitating robust supplier qualification and management. Geopolitical risks, trade policies, and shipping logistics can impact availability and cost.
• Logistics and Distribution: Efficient warehousing and distribution networks are required to deliver products to wholesalers, pharmacies, and hospitals worldwide. Cold chain logistics are generally not required for the final solid dosage forms under standard conditions, but controlled ambient temperatures are crucial.
• Inventory Management: Balancing inventory levels to meet demand while minimizing holding costs is a continuous challenge. Supply chain disruptions can deplete buffer stocks quickly.
• Resilience and Redundancy: Manufacturers often establish multiple qualified suppliers for critical raw materials and may have multiple manufacturing sites to mitigate risks associated with single points of failure.
• Regulatory Compliance in Transit: Ensuring that the supply chain adheres to all relevant import/export regulations, transportation safety standards, and product integrity requirements in different countries is complex.

The supply chain for amoxicillin/clavulanate potassium is a mature but complex global network. Investments in vertical integration, strategic supplier partnerships, and advanced supply chain analytics can provide competitive advantages.

Key Takeaways

Amoxicillin/clavulanate potassium represents a mature antibiotic market with established therapeutic value and broad clinical use. The intellectual property landscape is dominated by expired composition of matter patents, with remaining patent protection focused on manufacturing processes, novel formulations, and specific medical uses, extending into the mid-to-late 2020s and beyond for some innovations.

The market is characterized by intense generic competition, leading to significant price erosion and high volume sales. Investment fundamentals are driven by manufacturing efficiency, economies of scale, and robust supply chain management rather than rapid revenue growth from new product launches. Key risks include ongoing price compression, stringent regulatory compliance requirements, potential impacts of antimicrobial stewardship programs, and global supply chain vulnerabilities.

FAQs

1. Are there any active composition of matter patents for amoxicillin/clavulanate potassium? No, the original patents covering the chemical structures of amoxicillin and clavulanate potassium have long expired, making these APIs generic.

2. What types of patents still offer protection for amoxicillin/clavulanate potassium products? Remaining patent protection typically covers specific manufacturing processes, novel pharmaceutical formulations (e.g., enhanced stability, taste masking), and new therapeutic uses or dosage regimens.

3. What is the primary driver of profitability for companies manufacturing amoxicillin/clavulanate potassium? Profitability is primarily driven by manufacturing efficiency, cost optimization, economies of scale, and secure market share in a high-volume, price-competitive generic market.

4. What are the main risks associated with investing in the amoxicillin/clavulanate potassium market? Major risks include severe price erosion due to generic competition, stringent regulatory compliance demands, the potential for antimicrobial stewardship programs to influence prescribing habits, and vulnerabilities in the global supply chain.

5. How does regulatory compliance impact manufacturers of amoxicillin/clavulanate potassium? Manufacturers must adhere strictly to Good Manufacturing Practices (GMP), pharmacopoeial standards, and stringent quality control measures. Non-compliance can lead to severe penalties, product recalls, and loss of market authorization.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Drug Development Process. Retrieved from https://www.fda.gov/drugs/development-approval-process-drugs/drug-development-process

[2] European Medicines Agency. (n.d.). How to apply for authorisation. Retrieved from https://www.ema.europa.eu/en/human-regulatory-development-procedures/authorisation/how-apply-authorisation

[3] World Health Organization. (2019). Global action plan on antimicrobial resistance 2016–2020. Retrieved from https://www.who.int/publications/i/item/9789241511666

[4] U.S. Pharmacopeia. (n.d.). USP-NF Online. Retrieved from https://www.uspnf.com/

[5] GlaxoSmithKline. (n.d.). Our Medicines. Retrieved from https://www.gsk.com/en-gb/products/